Association of impaired glucose metabolism in morbid obesity with hypoadiponectinaemia

Experimental and Clinical Endocrinology and Diabetes

Volumn 116, Issue SUPPL. 1, 2008, Pages

  Schinner, Sven ^a   Kempf, K ^b   Overmann, H ^a   Willenberg, H S ^a   Schott, M ^a   Rose, B ^b   Scherbaum, W A ^a   Herder, C ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adiponectin; Diabetes mellitus; Inflammation; Obesity; Peripheral blood

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 6; MACROPHAGE CHEMOTACTIC FACTOR; MACROPHAGE CHEMOTACTIC FACTOR 1; MESSENGER RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPOADIPONECTINEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; CHEMOKINE CCL2; COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; OBESITY, MORBID; RNA, MESSENGER;

EID: 54549112058     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081490     Document Type: Article

References (54)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005: 365: 1415-1428
2. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabet Med 2005; 22: 674-682
3. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-643
4. Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc 2006: 81: S5-S10
5. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486
6. Kempf K, Rose B, Herder C, Haastert B, Fusbahn-Laufenburg A, Reifferscheid A et al. The metabolic syndrome sensitizes leukocytes for glucose-induced immune gene expression. J Mol Med 2007; 85: 389-396
7. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
8. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-1050
9. Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Activation of peripheral blood CD14+monocytes occurs in diabetes. Diabetes 2005; 54: 2779-2786
10. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007; 92: 1023-1033
11. Weisberg SP, MacCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808
12. Xu H, Barries GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830
13. Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, Busse R et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004; 53: 1285-1292
14. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200
15. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997; 82: 1313-1316
16. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9: 414-417
17. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 805-812
18. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334
19. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 2384-2389
20. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007; 30: 854-860
21. Esposito K, Pontillo A, Palo C Di, Giugliano G, Masella M, Marfella R et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799-1804
22. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-809
23. Yener S, Demir T, Akinci B, Bayraktar F, Kebapcilar L, Ozcan MA et al. Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus. Diabetes Res Clin Pract 2007; 76: 193-198
24. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 2006; 30: 1347-1355
25. Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007; 293: E656-E665
26. Herder C, Schneitler S, Rathmann W, Haastert B, Schneitler H, Winkler H et al. Low-grade inflammation, obesity and insulin resistance in adolescents. J Clin Endocrinol Metab 2007; 92: 4569-5474
27. Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Hoile R et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005: 54: S11-S17
28. Glanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 1564-1571
29. Fogelstrand L, Hulthe J, Hulten LM, Wiklund O, Fagerberg B. Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance. Diabetologia 2004; 47: 1948-1952
30. Sell H, Eckel J, Dietze-Schroeder D. Pathways leading to muscle insulin resistance - the muscle - fat connection. Arch Physiol Biochem 2006; 112: 105-113
31. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006; 27: 762-778
32. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie 2004; 86: 779-784
33. Weyer C, Funahashi T, Tanaka S, Hotta K, Matwawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935
34. Kempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C et al. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm Metab Res 2007: 39: 595-600
35. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537-1545
36. Herder C, Hauner H, Haastert B, Rohrig K, Koenig W, Kolb H et al. Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4). Diabetes Care 2006; 29: 1626-1631
37. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099
38. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946
39. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-1881
40. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295
41. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29: S43-S48
42. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248
43. Herder C, Baumert J, Thorand B, Koenig W, Jager W de, Meisinger C et al. Chemokines as risk factors for type 2 diabetes results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 2006; 49: 921-929
44. Herder C, Kolb H, Koenig W, Haastert B, Muller-Scholze S, Rathmann W et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006; 29: 368-371
45. Herder C, Klopp N, Baumert J, Muller M, Khuseyinova N, Meisinger C et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002. Diabetologia 2008; 51: 276-284
46. Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C et al. Differential association of adiponectin with cardiovascular risk markers in men and women. The KORA survey 2000. Int J Obes (Lond) 2007; 31: 770-776
47. Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 432-441
48. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005: 28: 1757-1762
49. Lee DH, Silventoinen K, Jacobs Jr DR, Jousilahti P, Tuomileto J. Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004; 89: 5410-5414
50. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476
51. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006; 55: 2915-2921
52. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 54 (Suppl 2): S114-S124
53. Sell H, Dietze-Schroeder D, Kaiser U, Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006; 147: 2458-2467
54. Sell H, Kaiser U, Eckel J. Expression of chemokine receptors in insulin-resistant human skeletal muscle cells. Horm Metab Res 2007; 39: 244-249